Details for New Drug Application (NDA): 018081
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 018081 describes DEPAKENE, which is a drug marketed by Abbvie and is included in two NDAs. Additional details are available on the DEPAKENE profile page.
The generic ingredient in DEPAKENE is valproic acid. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the valproic acid profile page.
The generic ingredient in DEPAKENE is valproic acid. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the valproic acid profile page.
Summary for 018081
| Tradename: | DEPAKENE |
| Applicant: | Abbvie |
| Ingredient: | valproic acid |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 018081
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
